<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: New Safety Data on Pregnancy Outcomes in Women with MS Using Interferon Beta, Including Rebif®, Before and During First Trimester	</title>
	<atom:link href="https://www.novumpr.nl/2019/07/01/new-safety-data-on-pregnancy-outcomes-in-women-with-ms-using-interferon-beta-including-rebif-before-and-during-first-trimester/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.novumpr.nl/2019/07/01/new-safety-data-on-pregnancy-outcomes-in-women-with-ms-using-interferon-beta-including-rebif-before-and-during-first-trimester/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-safety-data-on-pregnancy-outcomes-in-women-with-ms-using-interferon-beta-including-rebif-before-and-during-first-trimester</link>
	<description>NovumPR press releases</description>
	<lastBuildDate>Mon, 01 Jul 2019 12:24:11 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.2</generator>
</channel>
</rss>
